October 13, 2018

BNTC: Benitec Biopharma Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	248.88
Enterprise Value ($M)	181.04
Book Value ($M)	64.18
Book Value / Share	2.76
Price / Book	3.88
NCAV ($M)	63.74
NCAV / Share	2.75
Price / NCAV	3.90

Profitability (mra)
Return on Invested Capital (ROIC)	-0.32
Return on Assets (ROA)	-0.98
Return on Equity (ROE)	-1.35

Liquidity (mrq)
Quick Ratio	15.01
Current Ratio	15.01

Balance Sheet (mrq) ($M)
Current Assets	68.33
Assets	68.77
Liabilities	4.59
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	-22.49
Net Income	-21.75
Earnings Per Share Basic And Diluted	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	-19.40
Cash from Investing	-0.18
Cash from Financing	68.03
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
12-06	13G/A	Janus Henderson Group Plc	11.60	207.17
11-18	13D/A	Suvretta Capital Management, Llc	49.90	62.30
11-14	SCHEDULE 13G	Nantahala Capital Management, LLC
11-13	13G/A	HBM Healthcare Investments (Cayman) Ltd.	9.70	22.56
11-07	SCHEDULE 13G/A	Franklin Resources Inc
04-11	13G/A	Adage Capital Partners Gp, L.l.c.	9.99	39.81
02-14	13G/A	Citadel Advisors Llc	3.60

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-11-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
2024-05-13	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-13	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPOR
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-01-24	2,119	10,060	21.06
2025-01-23	1,201	10,888	11.03
2025-01-22	1,116	4,330	25.77
2025-01-21	1,151	13,805	8.34
(click for more detail)

Similar Companies
BGM – BGM Group Ltd.	BIVI – BioVie Inc.
BMRA – Biomerica, Inc.	BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited

Financial data and stock pages provided by
Fintel.io

Related